Nanjing RegeneCore Biotech

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
IL-4 / IL-5 / IL-13Multispecific antibody
Chronic Obstructive Pulmonary DiseaseAsthma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
RC1416Phase 2Moderate to Severe Asthma
Est. primary completion 2027-10-25 · NCT07403487 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
RC1416Phase 2Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Est. primary completion 2028-05-31 · NCT07402551 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.